In an industry often characterized by polite corporate jargon and carefully curated public relations, the inaugural "Bullseye" event—hosted by MedCity News in Chicago this past July—broke the mold. By invitation only, the conference gathered a diverse coalition of stakeholders, including private equity firms, university endowments, family offices, and leadership from the payer, provider, and life sciences sectors. The objective was simple yet radical: to facilitate a forum where the "candid, honest, and provocative" perspectives typically whispered in private boardrooms could be broadcast loudly.
The resulting dialogues did not merely touch upon the mechanics of healthcare; they questioned the morality of the system itself. From the opaque, labyrinthine pricing structures of Pharmacy Benefit Managers (PBMs) to the "rat-in-a-maze" mentality currently stifling innovation, the event served as a clarion call for a systemic reckoning.
The Chronology of Disruption: Why Complexity Wins
The event, which concluded on July 23, was structured as a series of high-stakes panels that tracked the lifecycle of healthcare value—from the pharmacy counter to the venture capital boardroom.
The conversation ignited during a panel on the evolution of the pharmacy, moderated by Jay Rughani, a partner at Andreessen Horowitz. The focus: Why is the true cost of medication so shrouded in secrecy? AJ Loiacono, CEO of the transparent PBM Judi Health, offered an unvarnished diagnosis: complexity is a deliberate business model.
"One who loves complexity, who loves opacity, is someone who’s focused on profitability," Loiacono stated, pointing directly at the legacy PBM giants like UnitedHealthcare’s Optum Rx, Cigna’s Express Scripts, and CVS Health’s Caremark.
Loiacono’s critique spanned the entire supply chain. He argued that the U.S. federal government, the nation’s largest purchaser of drugs, is itself a contributor to the chaos. With five distinct pricing schedules—340B, Medicare, Medicaid, the Department of Defense, and the Veterans Affairs—the government fails to establish a singular price per drug. "If the federal government can’t get one price per drug, what chance does the average employer… have?" Loiacono asked. "They have zero chance, and oftentimes they are the ones that are being absolutely abused under this system."
The Anatomy of the Broken System
The "Bullseye" panels effectively mapped the mechanics of the current healthcare crisis. According to the speakers, the system relies on a "fictitious starting price" that is then whittled down by layers of rebates, discounts, price protection fees, and clinical access fees.
Loiacono noted that spread pricing—the practice of charging a plan sponsor more for a drug than what is paid to the pharmacy—is a relatively recent invention, originating in the 21st century alongside the vertical integration of insurers and pharmacy services.
Pharma’s Complicity
The discussion shifted to the pharmaceutical manufacturers themselves. While pharma leaders often argue that their net prices remain stable relative to inflation and that PBM-driven list prices are the true culprit, the consensus at Bullseye was that manufacturers are equally responsible.
"I think if pharma was brave enough, they could do it, but they need to abandon the model of formulary access," Loiacono asserted. He suggested that brand managers are currently incentivized to "win" under the current murky gross-to-net system, which ultimately punishes patients who lack intelligent representation or high-level advocacy.
The Moral Awakening: "Rats in a Maze"
Perhaps the most visceral moment of the event occurred during a panel featuring nonprofit health plan CEOs. Sachin Jain, CEO of SCAN Health Plan, challenged the industry to move beyond its role as passive participants in a broken incentive structure.
"Congress does not have the capacity to overcome special interests," Jain stated. "If we’re going to really rely on that, then we are admitting to ourselves that we’re not knights, but we’re actually pawns."
Jain’s rhetoric was a direct call for a "civil rights movement" in healthcare. He argued that the industry has become a collective of "rats in a maze," chasing incentives that bear no resemblance to the actual needs of patients. He urged executives to shed their corporate personas and reclaim their moral agency, citing the 2014 decision by CVS Health to stop selling cigarettes as the "single most courageous act" in recent corporate healthcare history. That move, he noted, demonstrated that leadership could, in fact, shift market behavior and improve public health outcomes.
Collective Culpability and Institutional Reform
The "Bullseye" attendees did not shy away from the question of who is responsible for the current state of healthcare. Paul Markovich, CEO of Ascendiun (parent company of Blue Shield of California), offered a blunt admission: "It’s our own damn fault collectively."
Markovich argued that insurers, who control payment flows and administrative burdens, possess the greatest influence to force systemic change. He pointed to Blue Shield of California’s recent, aggressive move to restructure its prescription drug model by severing ties with legacy PBMs in favor of more transparent partners like Amazon Pharmacy, Abarca Forward, and Mark Cuban’s Cost Plus Drugs.
"I was told that the pharmacy benefit managers are so big, they’re so strong, they’re powerful, like you can’t mess with them," Markovich recounted. "And now I got people saying, ‘That rebate model is dead, right?’"
The Investment Frontier: AI and the New Revenue Paradigm
While the morning sessions focused on the moral and structural failings of the current system, the afternoon pivoted toward the future of healthcare investment. The focus shifted to Artificial Intelligence, with a surprising reversal of the traditional cost-reduction narrative.
Jo Natauri, founder and managing partner of Invidia Capital Management, argued that for two decades, health tech was synonymous with "cost reduction." With AI, however, the paradigm is shifting toward "revenue and margin opportunity."
However, this optimism was tempered by a warning regarding investor competence. Shubhra Jain, chief business officer at Hippocratic AI and a former investor, argued that many venture capitalists lack the technical expertise to differentiate between "native" AI companies and mere "wrapper" companies that simply repackage existing models.
"Diligencing the AI side of things is quite frankly something many investors just don’t know how to do," she explained. The stakes are immense: "The capex, it can totally turn the company upside down very, very quickly, more so than any other sort of model."
Implications for the Future
The inaugural Bullseye event made one thing abundantly clear: the healthcare industry is entering a period of forced transparency. The "normalization of the abnormal"—as Sachin Jain described the industry’s tolerance for inequity—is becoming increasingly unsustainable.
The implications are twofold:
- The Death of Opacity: As more organizations like Blue Shield of California move toward transparent PBM models, the pressure on legacy players to justify their "spread pricing" will intensify.
- The New Due Diligence: The rise of AI as a revenue-generating asset, rather than just a cost-saving tool, requires a new breed of investor. Firms that fail to develop internal technical expertise will find themselves funding the wrong winners in the AI arms race.
As Bullseye moves into its second year, the event has established itself as a necessary pressure valve for the industry. It is a space where the "back door" access enjoyed by healthcare elites is replaced by an interrogation of the front door: how the system treats the elderly, the poor, and the average employer.
For those operating within the healthcare ecosystem, the message from Chicago was clear: the status quo is not a natural law; it is a choice. And for the first time in a long time, the industry’s most influential leaders are openly discussing the cost of that choice.
